The Multiplier That Turns Early Traction Into Market Momentum There's a slide in nearly every MedTech deck labeled "Partners." It's a wall of logos sorted by prestige. Most of them have never moved a single unit. That's the trap. In the U.S. market, a partnership is either a multiplier or a distraction wearing a press release. There is no middle ground. And the odds aren't your friend. The failure rate for strategic alliances is famously grim, commonly pegged at around half.

Your Product Doesn't Speak for Itself. Neither Does Your Website. One of the biggest myths in MedTech is that great technology sells itself. It doesn't. If it did, hospitals would be full of incredible products that nobody's ever heard of instead of products backed by companies that built strong commercial engines. The reality is much less satisfying. The moment a hospital stakeholder can't immediately explain what your product does, why it matters, and why they should care,

Every medtech founder eventually faces the same uncomfortable question: how do we talk about what this product does without overstepping what the FDA cleared us to say? Under-claim, and you waste the evidence you spent millions to generate. Over-claim, and you invite a warning letter, a stalled hospital deal, or both. FDA clearance proves your product is safe. Your documentation proves your company is trustworthy. Here's what U.S. hospitals actually evaluate before they buy.